Subject(s)
Diabetic Angiopathies/complications , Glycosaminoglycans/therapeutic use , Heparinoids/therapeutic use , Hyperlipidemias/drug therapy , Adult , Aged , Drug Evaluation , Female , Glucuronates/therapeutic use , Humans , Hypercholesterolemia/drug therapy , Hyperlipidemias/etiology , Male , Middle Aged , Triglycerides/bloodABSTRACT
In insulin-dependent diabetics high GH values are usually observed. The OGTT does not modify these levels. It was observed that CB 154 (2-Br-alpha ergocryptine) seems capable of lowering GH in acromegalics. We thought it pertinent to check whether or not CB 154 could reduce GH also in diabetics. OGTT was performed in insulin-dependent diabetic patients; 5 days later the same test was repeated after pretreatment with 2.5 mg of CB 154. Serum IRI, GH, hPRL levels and blood glucose values were checked during the test. Significant GH and hPRL variations were not observed after OGTT in the diabetic subjects examined; IRI was always absent, and glycemia followed the model of the diabetic curve. On the contrary, after pretreatment with CB 154, we observed: 1) hPRL reduction; 2) GH increase, sometimes as early as 30 min after OGTT; 3) IRI was never present and blood glucose levels were lower than the values observed with glucose alone. Contrary to what is observed in acromegalics, CB 154 is unable to lower the increased GH levels normally present in insulin-dependent diabetics. After pretreatment with CB 154, OGTT seems to release GH, which is not observed after glucose alone. This can be accounted for only by postulating an antagonism at the hypothalamic level between the adrenergic and serotoninergic pathways of GH stimulation.
Subject(s)
Blood Glucose/metabolism , Diabetes Mellitus/blood , Growth Hormone/blood , Insulin/blood , Prolactin/blood , Adolescent , Adult , Diabetes Mellitus/drug therapy , Ergolines/metabolism , Ergolines/therapeutic use , Glucose Tolerance Test , Humans , Hypothalamus/metabolism , Male , Pituitary Hormone-Releasing Hormones/biosynthesisSubject(s)
Hepatectomy , Insulin/metabolism , Islets of Langerhans/physiology , Liver/physiology , Animals , Blood Glucose/analysis , Dogs , Insulin SecretionABSTRACT
The incretion was studied in eight male normal subjects control of hPRL incretion. The incretion of hPRL after infusion of SULPIRIDE (100 mg) by e.v. was studied in eight male normal subjects. Three days later the load of sulpiride was repeated after pretreatment (two hours) with C.B.-154 (2,5 mg). After CB-154 pretreatment the levels of hPRL were significantly lower. Cb-154 is able to reduce incretion of hPRL, also after stimulation with Sulpiride by double mechanism.
